In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

En­laza Ther­a­peu­tics raised $100 mil­lion to de­vel­op per­ma­nent­ly bind­ing an­ti­body-drug con­ju­gates for can­cer with a goal of bring­ing them in­to the first-ever hu­man stud­ies. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER